In previous studies, the texture characteristics or radiomics based on 18F-FDG PET/CT have been used to predict the EGFR and KRAS mutation status in patients with NSCLC, to evaluate NSCLC radiation tumor response, to predict the prognosis of patients with NSCLC after stereotactic body radiotherapy, and to stratify the risk of patients with poor prognosis. This evidence concerns the gene KRAS and non-small cell lung carcinoma.